Objectives/Hypothesis: At our institution, any liver transplant candidate with a recent history of smoking combined with daily use of alcohol prior to a 6-month sobriety period warrants formal evaluation by otolaryngology. Given the significant resource consumption and lack of evidence in support of this strategy, we sought to determine the effectiveness of these guidelines in detecting head and neck cancer.
INTRODUCTION
Head and neck cancer encompasses epithelial malignancies that arise from the paranasal sinuses, nasal cavity, oral cavity, pharynx, and larynx. The overwhelming majority of these malignancies are head and neck squamous cell carcinoma of the head and neck (HNC). HNC is the sixth most common type of cancer, representing about 6% of all cases and accounting for roughly 650,000 new cancer cases and 350,000 cancer deaths worldwide each year. In the United States in 2007, an estimated 45,660 new cases were diagnosed, and 11,210 deaths were caused by HNC. 1 Several known risk factors exist for HNC, most notably tobacco and alcohol exposure. There is a relative risk of 1.5 to 10 for tobacco alone for various HNC sites. 2 Case-control studies have demonstrated the carcinogenic effect of alcohol on the oropharynx with odds ratio (OR) of 8.8 for heavy drinkers (consuming >30 alcoholic drinks/week). There is a markedly multiplicative effect of tobacco and alcohol on the development of HNC in this region, with an OR of 37.7 for males who are both heavy drinkers and heavy smokers (smoking >2 packs per day for 20þ years). 3 Alcoholic liver disease (ALD) is the second most common cause of end-stage liver disease leading to an orthotopic liver transplant (OLT), after viral hepatitis. 4 International and domestic studies report between 52% and 54% of all potential OLT recipients (including non-ALD etiologies) regularly use both alcohol and tobacco prior to the abstinence period. 5, 6 Given the effects of alcohol and smoking on the development of HNC, the patient population requiring OLT theoretically faces a higher likelihood of developing HNC. With greater than one half of liver transplant candidates exposed to the synergistic effect of alcohol and tobacco on HNC, screening for HNC may be beneficial at some level in the pre-OLT period. The spectrum of screening for HNC ranges from visual inspection and manual palpation of the oral cavity and oropharynx by a general practitioner to flexible fiberoptic nasopharyngolaryngoscopy by the otolaryngologist. The latter intervention requires significantly greater healthcare resources yet serves as the gold standard for cancer diagnosis by virtue of its complete visualization of the upper aerodigestive tract.
At present, uniform screening guidelines prior to transplantation do not exist. Individual transplant centers use current evidence in combination with past experience to formulate hospital protocols. At the University of Pittsburgh Medical Center (UPMC) Starzl Transplantation Institute, the governing protocol for at least the last 10 years mandates that liver transplantation candidates smoking tobacco of any kind in the past year, combined with regular daily use of alcohol, receive an outpatient otolaryngology consult for formal evaluation of HNC. Given the significant resources consumed by outpatient otolaryngology referrals and subsequent work-up, our primary aim was to study the effectiveness of this protocol in detecting HNC prior to transplantation.
MATERIALS AND METHODS
The study protocol was approved by the University of Pittsburgh's institutional review board in December 2009. Given the lack of a single database with the information required to answer our objective, a two-part approach was taken to seek liver transplantation patients evaluated for HNC. First, an electronic search was conducted from the electronic billing records for all outpatient otolaryngology evaluations in the general and head and neck oncology divisions from January 1, 1999 to January 1, 2010. This result list was matched by name, date of birth, and medical record number against the Electronic Database Interface for Transplantation (EDIT), a clinical registry maintained by the University of Pittsburgh Starzl Transplantation Institute since 1994. Second, electronic otolaryngology billing records from all divisions were queried by referring physician being in the liver transplantation department. These results were again matched against the EDIT as mentioned previously.
Patients common to the otolaryngology billing records and EDIT from both search strategies were further investigated based on two methods. These two strategies were related and semioverlapping in an attempt to capture the intended population. The first strategy filtered patient billing records based on otolaryngology clinic visits occurring within 180 days after liver transplant evaluation. These records were then examined for associated ICD-9 codes for diagnosis of HNC. ICD-9 codes considered as HNC included lips, oral cavity, and pharynx (140-149), nose and paranasal sinuses (160), larynx (161), and those associated with unknown primaries (195 and 196) .
The second method searched the National Cancer Institute-funded University of Pittsburgh Cancer Institute's Head and Neck Organ-Specific Database (H&N OSD). This clinical database contains patients with tissue-proven HNC diagnoses or those who have received the first part or all of their treatment at the UPMC. The matches were then filtered based on patient billing records indicating that the visit to the otolaryngology clinic occurred within 180 days after liver transplant evaluation. In an attempt to validate our research findings, all attending physicians (n ¼ 7) currently employed at our institution involved in HNC screening were asked to recall having discovered suspicious lesions from this patient population.
RESULTS
A total of 70,534 patient encounters were seen in the head and neck surgical oncology and general otolaryngology outpatient clinic over the 11-year period. One hundred fourteen patient encounters in all otolaryngology outpatient clinics were identified based on a search by referring physician being in the transplantation department over the same 11-year interval ( Fig. 1 ). Based on EDIT, 815 (involving 794 unique patients) of the 7,743 encounters seen by liver transplantation from 1999 to 2009 were common to otolaryngology billing records. Of the 794 patients, 580 patients had been seen in the otolaryngology clinic within 6 months of liver transplant evaluation. Eight patients were evaluated twice, and only the first evaluations were considered. These 580 patients were considered the population of interest, as the chronology of the liver transplantation and otolaryngology evaluations were highly suggestive of HNC screening referral. Table I demonstrates baseline clinical data, including age, gender, race, transplantation received, and alcoholic cirrhosis, as primary indications for transplant for the 580 patients in our selection.
The administrative data provided ICD-9 diagnoses and procedure codes for each patient encounter. Table II illustrates the number of patients evaluated by flexible fiberoptic laryngoscopy in the otolaryngology clinic and the relevant findings per billing records. Additional information in the table includes number of patients with office biopsy by the site of the lesion.
Eight of the 580 patients had an ICD-9 code of HNC from billing records. The H&N OSD detected five patients from the list of 580 patients with an HNC diagnosis. Two of these patients were common to the eight patients from the first strategy, whereas three were new hits (Fig. 2) . Adding the eight patients from ICD-9 codes and three patients from the OSD, 11 patient charts were further explored.
Subsequent chart reviews for these 11 patients revealed eight patients with previous diagnosis of HNC, two patients with development of HNC post-transplantation (diagnosis made at 3 years and 7 years following transplant), and one patient with thyroid cancer miscoded as HNC. As a result, no patients were found to have HNC from the administrative and clinical databases at the time of screening.
Otolaryngology faculty in the head and neck and general divisions currently employed at our institutions were contacted via e-mail or face-to-face correspondence. Of the 580 patients, 63% were seen primarily by one of the seven physicians contacted. The physicians were asked to recall any cancers discovered on HNC screening from liver transplantation referral. Six of the seven attending physicians did not recall ever detecting a cancer on screening. One attending physician vividly recalled the patient's name, approximate year of diagnosis, site of lesion, and subsequent treatment for the cancer. Our database had a record of this patient's visit in 2004, but no record of this patient's visit in 1999 was found in EDIT. Further chart exploration, however, revealed that this patient had been seen by otolaryngology in 1999 for an HNC screening referral from liver transplantation. At that time, a suspicious oropharyngeal tongue and ipsilateral neck mass was noted. Biopsy of both sites in the operating room revealed squamous cell carcinoma of the oropharynx. This patient was treated with radiation therapy at that time, re-evaluated in 2004 for liver transplantation (after 5 cancer-free years), and successfully transplanted later in 2004. Therefore, out of 581 (580 from the database and one from attending recall) patient evaluations performed by the otolaryngologist for potential HNC screening prior to liver transplantation, one (0.17% of evaluations) case of HNC was detected. Applying the Poisson exact distribution via STATA statistical software release 10 (StataCorp LP, College Station, TX), a 95% confidence interval of 0.0044% to 0.96% of evaluations was obtained.
DISCUSSION
In an era of heightened focus on resource allocation, this article evaluated the effectiveness of the screening referral pattern of our institution's highly active transplant program. This is the first study to examine the yield from the screening of liver transplantation candidates for HNC. Our results demonstrate that one of the 581 patients seen for HNC screening yielded a positive result. One method to evaluate the effectiveness of this intervention is through a societal cost-benefit ratio. Costs of screening include indirect costs (patient, caregiver, and physician time) and costs of service. Given the difficulty in measuring indirect costs, we will include costs of service using Medicare reimbursement data. The cost of a level IV ear, nose, and throat consultation ($152), added to 27% (percent of patients evaluated by flexible fiberoptic laryngoscopy) of the cost of flexible fiberoptic laryngoscopy ($70), equals an average patient cost of $171 per visit. Multiplying this value by the 581 patients evaluated equals roughly $100,000 per positive screen. This cost-benefit ratio represents the amount of healthcare dollars spent (time costs excluded) to find one HNC case in patients evaluated for liver transplantation. As a retrospective review, this study suffered from several shortcomings. A prospective study would definitively have answered the study question; however, given the rarity of the disease, the required sample size and follow-up rendered such a study extremely difficult. The clinical databases proved incomplete as evidenced by the physician recall of the lone positive screen. The databases also do not contain complete information regarding measurements of patient alcohol and tobacco usage, which would have allowed for characterization of relative risks for HNC. Additionally, the reason for otolaryngology referral was inferred from patient charts but not clearly documented. Other missing information included HNC-related presenting symptomatology such as hoarseness, otalgia, and dysphagia at the visit to the liver transplantation team. Apart from flexible fiberoptic laryngoscopy recorded in the billing records, details of the HNC screening evaluation, such as evaluation by indirect laryngoscopy, were not known. Information regarding patients who were lost to follow-up after the liver transplantation or received their post-transplant care at an outside institution was not available.
Despite the above-mentioned limitations of this retrospective review, the findings of this study are sufficient to conclude that the current screening protocol needs to be re-examined. In particular, a thorough history and physical examination of patients with an alcohol and tobacco history is warranted. High-risk patients should receive a thorough review of systems including common presenting symptoms of head and neck malignancy. These symptoms include pain, bleeding, ulceration, hoarseness, otalgia, and/or dysphagia. 7 Orderly visual inspection of the entire oral and oropharyngeal mucosa with particular attention to the tongue, floor of mouth, soft palate, uvula, tonsillar pillars, and the lingual aspects of the retromolar trigones should be performed in this subpopulation. This examination can be performed inexpensively and quickly by trained healthcare professionals with both a high sensitivity and specificity for disease detection. 8 Patients who are found to have positive findings on head and neck review of symptoms and/or physical examination should be referred to otolaryngologists for further evaluation.
CONCLUSION
At present, screening for HNC among smokers evaluated for liver transplantation has a societal cost (time costs excluded) of $100,000 per individual detected based on one positive screening out of 581 evaluations. The acceptability of this cost-benefit ratio of screening is subject to debate given the scarcity of organs and subsequent investment of resources required for liver transplantation. The overall cost of transplanting a patient with occult HNC is unknown. Nevertheless, it appears evident that the use of tobacco and alcohol history alone as per current screening guidelines do not optimally capture high-risk individuals. Future steps toward smarter resource-effective screening include recording patient symptomatology and performing a complete head and neck physical examination.
